The reduction in MACCE for continued thienopyridine was greater for patients with MI ( 3.9 % vs. 6.8 % ; p < 0.001 ) compared with those with no MI ( 4.4 % vs. 5.3 % ; p = 0.08 ; interaction p = 0.03 ) .